KBC Group NV Buys 514,580 Shares of Kenvue Inc. (NYSE:KVUE)

KBC Group NV lifted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 114.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 966,160 shares of the company's stock after acquiring an additional 514,580 shares during the period. KBC Group NV owned 0.05% of Kenvue worth $22,348,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Riverview Trust Co purchased a new position in shares of Kenvue during the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC bought a new stake in Kenvue in the third quarter worth $35,000. Studio Investment Management LLC grew its stake in shares of Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock worth $45,000 after acquiring an additional 845 shares during the last quarter. Deseret Mutual Benefit Administrators increased its holdings in shares of Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock valued at $45,000 after acquiring an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Kenvue in the 2nd quarter worth about $61,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Up 1.0 %

KVUE opened at $23.84 on Friday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.13. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market cap of $45.70 billion, a price-to-earnings ratio of 43.34, a price-to-earnings-growth ratio of 2.10 and a beta of 1.36. The firm's fifty day moving average is $22.75 and its 200 day moving average is $20.65.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the previous year, the firm earned $0.31 earnings per share. The company's quarterly revenue was down .4% compared to the same quarter last year. On average, sell-side analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. Kenvue's dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of analyst reports. UBS Group raised their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Wednesday, August 7th. Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 target price on the stock. in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.